The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...

Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, ...

Corona Remedies acquires cardiology and women's healthcare brands from Bayer, entering new segments ahead of IPO.

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...

Jeremy Siegel, professor emeritus of finance at the University of Pennsylvania’s Wharton School of Business and Wisdom Tree chief economist, appeared on CNBC’s ‘Squawk Box’ to ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.